Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imlifidase in ANCA-associated vasculitis with pulmonary hemorrhage
2021-004706-22Phase 2Active
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Sep 2022
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, single-arm trial of efgartigimod alfa in anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV), granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) and 1 more, sponsored by Charité – Universitätsmedizin Berlin. Started Sep 2022; status: active.
02
Drugs
efgartigimod alfa
03
Conditions
anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV)granulomatosis with polyangiitis (GPA)microscopic polyangiitis (MPA)pulmonary alveolar hemorrhage (DAH)
Beyond the preview
Go deeper on 2021-004706-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004706-22.